Masimo (NASDAQ:MASI) Issues FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.620-5.790 for the period, compared to the consensus estimate of 5.320. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Masimo Trading Up 2.8%

NASDAQ:MASI traded up $4.05 during trading hours on Tuesday, reaching $149.01. 1,439,249 shares of the stock were exchanged, compared to its average volume of 639,869. The company has a market capitalization of $8.09 billion, a price-to-earnings ratio of -17.49 and a beta of 1.28. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. Masimo has a twelve month low of $133.70 and a twelve month high of $194.88. The business has a 50-day moving average of $144.80 and a two-hundred day moving average of $154.07.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The company had revenue of $617.00 million for the quarter. On average, equities analysts predict that Masimo will post 4.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Zacks Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Piper Sandler increased their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. BTIG Research restated a “buy” rating and set a $198.00 price target on shares of Masimo in a report on Thursday, September 11th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $194.60.

Insider Activity

In other news, Director William R. Jellison bought 3,000 shares of the firm’s stock in a transaction on Monday, August 11th. The shares were purchased at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares in the company, valued at $699,244.20. This represents a 167.60% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 9.70% of the company’s stock.

Institutional Trading of Masimo

Hedge funds have recently modified their holdings of the stock. State Street Corp raised its stake in Masimo by 0.7% in the second quarter. State Street Corp now owns 1,486,394 shares of the medical equipment provider’s stock valued at $250,041,000 after purchasing an additional 10,403 shares in the last quarter. Durable Capital Partners LP lifted its position in Masimo by 3.4% during the second quarter. Durable Capital Partners LP now owns 1,163,898 shares of the medical equipment provider’s stock valued at $195,791,000 after buying an additional 38,279 shares during the period. Viking Global Investors LP purchased a new position in shares of Masimo in the 2nd quarter worth about $129,096,000. Ameriprise Financial Inc. raised its position in Masimo by 86.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 394,487 shares of the medical equipment provider’s stock worth $66,361,000 after buying an additional 182,701 shares during the last quarter. Finally, Bamco Inc. NY increased its position in shares of Masimo by 21.2% during the 2nd quarter. Bamco Inc. NY now owns 384,589 shares of the medical equipment provider’s stock valued at $64,696,000 after purchasing an additional 67,307 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.